top of page
Search

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

  • decodeMR Team
  • 11 hours ago
  • 1 min read

02/04/2026















Immunovant announced Phase 3 results for batoclimab in thyroid eye disease (Ref)


Immunovant announced topline results from its two Phase 3 (GO) studies that evaluated batoclimab (an FcRn antagonist) for the treatment of adult patients with active, moderate-to-severe thyroid eye disease (TED)


  • The studies failed to meet their primary endpoint of achieving  ≥2mm proptosis responder rate at Week 24, following 12 weeks of high-dose and 12 weeks of low-dose batoclimab treatment


  • Safety results were consistent with previous findings, and no new safety signals were identified




bottom of page